Fate Therapeutics (FATE) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress
May 10, 2018 4:01 PM EDTNo Cancer Relapse Reported in Phase 1 PROTECT Study of ProTmune
Anti-tumor Activity with No Dose-limiting Toxicities Observed in Initial Phase 1 Dose Escalation of FATE-NK100 in Advanced Solid and Liquid Tumors
IND for Off-the-Shelf NK Cell Product FT500 Remains on Track for 2Q18 Submission
Off-the-Shelf Dual-targeted CAR T-cell Product Demonstrates CD19 and CD20 Anti-tumor Activity in Preclinical Studies of Antigen Escape
SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the... More
